The mature Japanese CRM device market will remain flat through 2029, characterized by low generator unit volume growth, rising ICM procedure volumes, and price erosion. The uptake of premium-priced devices such as CRT devices, leadless pacemakers, and S-ICDs will help mitigate the downward pressure of reimbursement cuts over the forecast period. However, the COVID-19 global pandemic will have a negative impact on the Japan CRM device market, resulting in lost procedure volumes in the short term followed by a period of recovery.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the Japanese cardiac rhythm management device market across a 10-year period.
Adoption of novel devices will offset waning revenue for traditional devices in the Japanese CRM market.
What is the predicted uptake of novel devices such as leadless pacemakers and S-ICDs? Will leadless pacemakers and S-ICDs become the standard of care?
To what extent does the uptake of leadless pacemakers like Medtronic's Micra and Boston Scientific's EMBLEM S-ICDs offset declining revenue in other markets?
New-generation miniature ICMs like Medtronic's Reveal LINQ have experienced strong uptake, how does this affect competitive standings? Have other ICM competitors met Medtronic's challenge? How does the availability of this device affect sales of other CRM devices?
The COVID-19 global pandemic will have a negative impact on the CRM market in the short-term.
To what extent will the CRM market, which is made up of largely essential procedures, experience reduced procedure volumes? How will this differ from the nonessential ICM segment?
How will ongoing and planned clinical trials be affected by a strained health care system?
The mature CRM device market will remain highly saturated, which leads competitors to find innovations to achieve growth.
How do epidemiological trends and new technology influence growth in different pulse generator product segments? How are these trends different compared to the rapidly expanding ICM market?
How can individual competitors realize growth in this large but fairly mature market?
The MHLW's biennial reimbursement revisions are having a significant impact on pricing trends.
How are the MHLW's biennial reimbursement revisions different between device segments? What 2018 revisions will affect market growth?
How are the ASP trends for novel devices different compared to those for more established devices?
- Cardiac Rhythm Management Devices - Market Insights - Japan
Author(s): Suraj Nair, Masters in Bioprocess Technology
Suraj Nair is a Research Associate within the Cardiovascular Medtech Insights team at Decision Resources Group, specializing in the Electrophysiology Mapping and Ablation Devices Market. Suraj holds a Master’s degree in Bioprocess Technology from the Institute of Chemical Technology, Mumbai and has a prior experience of working in the biopharmaceutical industry for two years and in the market research industry for medical devices for a year.